Compounds, such as KSI-3716, demonstrated that successfully blocking complex formation of N-Myc-Max with DNA [38,39] would cease transcription of target gene promoters that drives tumorigenesis in bladder cancer, suggesting inhibition of N-Myc as a possible therapeutic approach [40]. Here, MYCN is linked to urinary bladder cancer.